메뉴 건너뛰기




Volumn 43, Issue 10, 2003, Pages 1344-1346

Physicians for the advancement of transfusion medicine: A new and distinct medical voice

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD BANK; BLOOD TRANSFUSION; EDITORIAL; ERYTHROCYTE DISORDER; HEMOPHILIA; HEMOSTASIS; PHYSICIAN; POLICY; PRACTICE GUIDELINE; THROMBOSIS; EDUCATION; HEALTH CARE POLICY; HUMAN; MEDICINE; STANDARD;

EID: 0142040275     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00582.x     Document Type: Editorial
Times cited : (5)

References (4)
  • 1
    • 0034846197 scopus 로고    scopus 로고
    • Universal WBC rediction: The case for and against
    • Vamvakas EC, Blachman MA. Universal WBC rediction: the case for and against. Transfusion 2001;41:692-712.
    • (2001) Transfusion , vol.41 , pp. 692-712
    • Vamvakas, E.C.1    Blachman, M.A.2
  • 2
    • 0033970908 scopus 로고    scopus 로고
    • Leukocyte reduction of blood components: Public policy and new technology
    • Dzik WH, AuBuchon J, Jeffries L, et al. Leukocyte reduction of blood components: Public policy and new technology. Transfus Med Rev 2000;14:34-52.
    • (2000) Transfus Med Rev , vol.14 , pp. 34-52
    • Dzik, W.H.1    AuBuchon, J.2    Jeffries, L.3
  • 3
    • 0003477433 scopus 로고    scopus 로고
    • Guidance for industry: Revised preventive measures to reduce the possible risk of transmission of Creutzfeld-Jacob disease (CJD) and variant Creutzfeld-Jacob disease (vCJD) by blood and blood products
    • January
    • Guidance for industry: revised preventive measures to reduce the possible risk of transmission of Creutzfeld-Jacob disease (CJD) and variant Creutzfeld-Jacob disease (vCJD) by blood and blood products. FDA Memorandum, January 2002.
    • (2002) FDA Memorandum


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.